NASDAQ:BGNE - Beigene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$139.01 +0.08 (+0.06 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$138.93
Today's Range$137.05 - $141.33
52-Week Range$105.19 - $220.10
Volume250,300 shs
Average Volume412,115 shs
Market Capitalization$8.26 billion
P/E Ratio-62.34
Dividend YieldN/A
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has strategic collaborations with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317; Merck KGaA to research and develop on BGB-290 and BGB-283; and MEI Pharma, Inc. to evaluate the safety and efficacy of ME-401, an investigational PI3K delta inhibitor in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BGNE



Sales & Book Value

Annual Sales$238.39 million
Book Value$15.02 per share


Net Income$-93,100,000.00
Net Margins-320.08%


Market Cap$8.26 billion

Beigene (NASDAQ:BGNE) Frequently Asked Questions

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) posted its earnings results on Wednesday, November, 7th. The company reported ($2.53) EPS for the quarter, beating analysts' consensus estimates of ($2.97) by $0.44. The business had revenue of $54.20 million for the quarter, compared to the consensus estimate of $47.06 million. Beigene had a negative net margin of 320.08% and a negative return on equity of 38.44%. The company's revenue for the quarter was down 75.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.54 EPS. View Beigene's Earnings History.

When is Beigene's next earnings date?

Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Beigene.

What price target have analysts set for BGNE?

11 equities research analysts have issued 1 year price objectives for Beigene's stock. Their predictions range from $138.00 to $215.00. On average, they anticipate Beigene's stock price to reach $178.7188 in the next year. This suggests a possible upside of 28.6% from the stock's current price. View Analyst Price Targets for Beigene.

What is the consensus analysts' recommendation for Beigene?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.

What are Wall Street analysts saying about Beigene stock?

Here are some recent quotes from research analysts about Beigene stock:
  • 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (1/15/2019)
  • 2. Maxim Group analysts commented, "This morning, Bristol-Myers Squibb (BMY – NR) announced it will acquire Celgene (CELG – NR) for ~$74B, projected to close 3Q19. BGNE shares were initially down ~30% but have climbed back to being down only ~10%. The pressure on the stock is due to the questions around the CELG/BGNE partnership for PD1, tislelizumab. There are two scenarios we see that can play out for BGNE, assuming the transaction closes: 1. BMY ends the partnership with BGNE: Most likely, in our view as BMY has Opdivo which generates ~$5B globally (and has its first approval in China). BMY can take back Revlimid in China, also likely. The positives for BGNE: ○ BGNE regains global rights to tislelizumab which is now in 10 ongoing pivotal trials, is closer to approval(s) and positions the company to get an even better deal than it got with CELG." (1/3/2019)

Has Beigene been receiving favorable news coverage?

News headlines about BGNE stock have trended neutral recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Beigene earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the immediate future.

Who are some of Beigene's key competitors?

Who are Beigene's key executives?

Beigene's management team includes the folowing people:
  • Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)
  • Dr. Amy C. Peterson M.D., Chief Medical Officer of Immuno-Oncology (Age 52)
  • Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)
  • Dr. Xiaobin Wu, Pres & Gen. Mang. of China

When did Beigene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who are Beigene's major shareholders?

Beigene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Hillhouse Capital Advisors Ltd. (7.47%), BlackRock Inc. (3.16%), Canada Pension Plan Investment Board (1.89%), Hillhouse Capital Management Ltd. (1.74%), Northern Trust Corp (0.95%) and Matthews International Capital Management LLC (0.41%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Institutional Ownership Trends for Beigene.

Which institutional investors are selling Beigene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Management Ltd., Bank of Montreal Can, Citigroup Inc., Bank of America Corp DE, California Public Employees Retirement System, First Trust Advisors LP, Tocqueville Asset Management L.P. and Brinker Capital Inc.. Company insiders that have sold Beigene company stock in the last year include Amy C Peterson, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Insider Buying and Selling for Beigene.

Which institutional investors are buying Beigene stock?

BGNE stock was bought by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., BlackRock Inc., Northern Trust Corp, Fiera Capital Corp, Geode Capital Management LLC, Legal & General Group Plc, Polar Capital LLP and Bellevue Group AG. View Insider Buying and Selling for Beigene.

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $139.01.

How big of a company is Beigene?

Beigene has a market capitalization of $8.26 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Beigene employs 900 workers across the globe.

What is Beigene's official website?

The official website for Beigene is

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]

MarketBeat Community Rating for Beigene (NASDAQ BGNE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  621
MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel